TSC22D2 and pancreatic adenocarcinoma: High expression of TSC22D2 was significantly associated with a worse prognosis in ICGC-PACA-CA samples (p < 0.001, Fig. 7A), which was similar in the TCGA-PAAD samples (p < 0.05, Supplementary Fig. 4A).